share_log

HC Wainwright & Co. Reiterates Buy on Reviva Pharmaceuticals, Maintains $14 Price Target

HC Wainwright & Co. Reiterates Buy on Reviva Pharmaceuticals, Maintains $14 Price Target

HC Wainwright & Co.重申買入Reviva Pharmaceuticals,維持14美元的目標價。
Benzinga ·  06/20 06:15

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Reviva Pharmaceuticals (NASDAQ:RVPH) with a Buy and maintains $14 price target.

HC Wainwright & Co.分析師Raghuram Selvaraju重申將Reviva Pharmaceuticals (納斯達克代碼:RVPH) 買入,目標價維持在$14。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論